As a potential target for cancer treatment, small molecules have been developed to act as inhibitors of Msi2. We need to consider the effect of this medication on patients with osteoporosis and other skeletal degenerative diseases.38,39 Realizing tissue-specific and spatiotemporal specificity to restore the normal expression of Msi2 will be crucial for the occurrence and development of the disease. This evidence concerns the gene MSI2 and osteoporosis.